General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model

European Journal of Medicinal Chemistry

Volumn 94, Issue , 2015, Pages 252-264

  Perrone, Maria Grazia ^a   Vitale, Paola ^a   Panella, Andrea ^a   Fortuna, Cosimo G ^b   Scilimati, Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

1,2,3 Triazoles; COX inhibition; Predictive pharmacometric model; Volsurf plus

Indexed keywords

1 (4 CHLOROPHENYL) 5 METHYL 4 PHENYL 1H 1,2,3 TRIAZOLE; 1 (4 FLUOROPHENYL) 5 METHYL 4 PHENYL 1H 1,2,3 TRIAZOLE; 1 (4 METHOXYPHENYL) 5 METHYL 4 (4 NITROPHENYL) 1H 1,2,3 TRIAZOLE; 1 (4 METHOXYPHENYL) 5 METHYL 4 [4 (METHYLSULFONYL)PHENYL] 1H 1,2,3 TRIAZOLE; 1 (4 METHOXYPHENYL) 5 METHYL 4 [4 (METHYLTHIO)PHENYL] 1H 1,2,3 TRIAZOLE; 1,2,3 TRIAZOLE DERIVATIVE; 1,4 BIS (4 METHOXYPHENYL) 5 METHYL 1H 1,2,3 TRIAZOLE; 4 (4 METHOXYPHENYL) 5 METHYL 1 [4 (METHYLSULFONYL)PHENYL] 1H 1,2,3 TRIAZOLE; 4 (4 METHOXYPHENYL) 5 METHYL 1 [4 (METHYLTHIO)PHENYL] 1H 1,2,3 TRIAZOLE; 4 (5 CHLOROFURAN 2 YL) 1 (4 METHOXYPHENYL) 5 METHYL 1H 1,2,3 TRIAZOLE; 4 (5 METHYL 4 PHENYL 1H 1,2,3 TRIAZOL 1 YL)BENZENAMINE; 4 (5 METHYL 4 PHENYL 1H 1,2,3 TRIAZOL 1 YL)PHENOL; 4 (FURAN 2 YL) 1 (4 METHOXYPHENYL) 5 METHYL 1H 1,2,3 TRIAZOLE; 4 (FURAN 2 YL) 5 METHYL 1 (4 NITROPHENYL) 1H 1,2,3 TRIAZOLE; 4 [1 (4 METHOXYPHENYL) 5 METHYL 1H 1,2,3 TRIAZOLE 4 YL]BENZENAMINE; 5 METHYL 1 (4 NITROPHENYL) 4 PHENYL 1H 1,2,3 TRIAZOLE; 5 METHYL 1 [4 (METHYLSULFONYL)PHENYL] 4 PHENYL 1H 1,2,3 TRIAZOLE; 5 METHYL 1 [4 (METHYLTHIO)PHENYL) 4 PHENYL 1H 1,2,3 TRIAZOLE; ARACHIDONIC ACID; CYCLOOXYGENASE 1 INHIBITOR; ISOXAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIAZOLE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; REGRESSION ANALYSIS; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEAST-SQUARES ANALYSIS; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84924696954     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.049     Document Type: Article

References (52)

1. M.G. Perrone, A. Scilimati, L. Simone, P. Vitale, Selective COX-1 inhibition: a therapeutic target to be reconsidered, Curr. Med. Chem. 17 (2010) 3769-3805.
2. 18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation, Eur. J. Med. Chem. 80 (2014) 562-568.
3. J.M. Schwab, R. Beschorner, R. Meyermann, F. Gözalan, H.J. Schluesener, Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury, J. Neurosurg. 96 (2002) 892-899.
4. 2 synthesis and lipid peroxidation after in vivo activation of Nmethyl-d-aspartate receptors in rat hippocampus, J. Neurochem. 93 (2005) 1561-1567.
5. R. Calvello, M.A. Panaro, M.L. Carbone, A. Cianciulli, M.G. Perrone, P. Vitale, P. Malerba, A. Scilimati, Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells, Pharmacol. Res. 66 (2012) 137-148.
6. E. Candelario-Jalil, A.C. de Oliveira, S. Gräf, H.S. Bhatia, M. Hüll, E. Muňoz, B.L. Fiebich, Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia, J. Neuroinflamm. 4 (2007) 25-37.
7. S.H. Choi, R. Langenbach, F. Bosetti, Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury, FASEB J. 22 (2008) 1491-1501.
8. J.R. Barrio, N. Satyamurthy, S. Huang, A. Petric, G.W. Small, V. Kepe, Dissecting molecular mechanisms in the living brain of dementia patients, Acc. Chem. Res. 42 (2009) 842-850.
9. M.G. Perrone, D.D. Lofrumento, P. Vitale, F. De Nuccio, V. La Pesa, A. Panella, R. Calvello, A. Cianciulli, M.A. Panaro, A. Scilimati, Selective Cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation, Pharmacology (2015) 22-28.
10. L. Di Nunno, P. Vitale, A. Scilimati, S. Tacconelli, P. Patrignani, Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal, J. Med. Chem. 47 (2004) 4881-4890.
11. M.G. Perrone, P. Vitale, P. Malerba, A. Altomare, R. Rizzi, A. Lavecchia, C. Di Giovanni, E. Novellino, A. Scilimati, Diarylheterocycle core ring features effect in selective COX-1 inhibition, Chem. Med. Chem. 7 (2012) 629-641.
12. P. Vitale, M.G. Perrone, P. Malerba, A. Lavecchia, A. Scilimati, Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles, Eur. J. Med. Chem. 74 (2014) 606-618.
13. V.S. Kristi, A.W. Barbara, Trends in Cancer Therapy: Role of Monoclonal Antibodies, Sem. Oncol. Nurs. 19 (2003) 169-209.
14. D.R. Buckle, D.J. Outred, C.J.M. Rockell, H. Smith, B.A. Spicer, Studies on 1,2,3-triazoles. (Piperazinylalkoxy)-[1]-benzopyrano-[2,3-d]-1,2,3-triazol-9(1H)- ones with combined H1-antihistamine and mast cell stabilizing properties, J. Med. Chem. 29 (1986) 2262-2267.
15. M.J. Genin, D.A. Allwine, D.J. Anderson, M.R. Barbachyn, D.E. Emmert, S.A. Garmon, D.R. Graber, K.C. Grega, J.B. Hester, D.K. Hutchinson, J. Morris, R.J. Reischer, C.W. Ford, G.E. Zurenko, J.C. Hamel, R.D. Schaadt, D. Stapert, B.H. Yagi, Substituent effects on the antibacterial activity of nitrogen-carbonlinked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis, J. Med. Chem. 43 (2000) 953-970.
16. J. Imanishi, Y. Morita, E. Yoshimi, K. Kuroda, T. Masunaga, K. Yamagami, M. Kuno, E. Hamachi, S. Aoki, F. Takahashi, K. Nakamura, S. Miyata, Y. Ohkubo, S. Mutoh, Pharmacological profile of FK881 (ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor, Biochem. Pharmacol. 82 (2011) 746-754.
17. S.P. Bathula, R. Vadla, Bioactivity of 1, 4-Disubstituted-1,2,3-Triazoles as cytotoxic agents against the various Human Cell Lines, Asian J. Pharm. Clin. Res. 4 (2011) 66-67.
18. G. Cruciani, P. Crivori, P.A. Carrupt, B. Testa, Molecular Fields in quantitative structure-permeation relationships: the VolSurf approach, Theochem 503 (2000) 17-30.
19. The VolSurf+ Manual available at: http://www.moldiscovery.com/docs/vsplus/.
20. H.C. Kolb, K.B. Sharpless, The growing impact of click chemistry on drug discovery, Drug Discov. Today 8 (2003) 1128-1137.
21. F. Wuest, X. Tang, T. Kniess, J. Pietzsch, M. Suresh, Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives, Bioorg. Med. Chem. 17 (2009) 1146-1151.
22. P. Vitale, S. Tacconelli, M.G. Perrone, P. Malerba, L. Simone, A. Scilimati, A. Lavecchia, M. Dovizio, E. Marcantoni, A. Bruno, P. Patrignani, Synthesis, pharmacological characterization and docking analysis of a novel family of diarylisoxazoles as highly selective COX-1 inhibitors, J. Med. Chem. 56 (2013) 4277-4299.
23. Y. Bourne, H.C. Kolb, Z. Radi, K.B. Sharpless, P. Taylor, P. Marchot, Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1449-1454.
24. D.R. Buckle, D.J. Outred, C.J. Rockell, H. Smith, B.A. Spicer, Studies on v-triazoles. antiallergic 9-oxo-1H,9H-benzopyrano[2,3-d]-v-triazoles, J. Med. Chem. 26 (1983) 251-254.
25. M.F. Mady, G.E.A. Awad, K.B. Jørgensen, Ultrasound-assisted synthesis of novel 1,2,3-triazoles coupled diaryl sulfone moieties by the CuAAC reaction, and biological evaluation of them as antioxidant and antimicrobial agents, Eur. J. M. Chem. 84 (2014) 433-443.
26. R. Alvarez, S. Velázquez, A. San Felix, S. Aquaro, E.D. Clercq, C.F. Perno, A. Karlsson, J. Balzarini, M.J. Camarasa, 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl)- beta-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity, J. Med. Chem. 37 (1994) 4185-4194.
27. Y.S. Sanghvi, B.K. Bhattacharya, G.D. Kini, S.S. Matsumoto, S.B. Larson, W.B. Jolley, R.K. Robins, G.R. Revankar, Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin, J. Med. Chem. 33 (1990) 336-344.
28. M. Journet, D. Cai, J.J. Kowal, R.D. Larsen, Highly efficient and mild synthesis of variously 5-substituted-4-carbaldehyde-1,2,3-triazole derivatives, Tetrahedron Lett. 42 (2001) 9117-9118.
29. b-enamino ester derivatives with 1,2,3-triazole, Heterocycl. Comm. 6 (2000) 421-426.
30. S. Shafi, M.M. Alam, N. Mulakayala, C. Mulakayala, G. Vanaja, A.M. Kalle, R. Pallu, M.S. Alam, Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-noceptive activities, Eur. J. Med. Chem. 49 (2012) 324-333.
31. N. Upmanyu, J.K. Gupta, K. Shah, P. Mishra, Synthesis of new 1,2,4-triazoles as anti-inflammatory and anti-nociceptive agents, Pharm. Chem. J. 45 (2011) 433-439.
32. K.M. Banu, A. Dinakar, C. Ananthanarayanan, Synthesis, characterization, antimicrobial studies and pharmacological screening of some substituted 1,2,3-triazoles, Indian J. Pharm. Sci. 4 (1999) 202-205.
33. L.P. Guan, Q.H. Jin, G.R. Tian, K.Y. Chai, Z.S. Quan, Synthesis of some quinoline-2(1H)-one and 1,2,4-triazol-[4,3-a]-quinoline derivatives as potent anticonvulsants, J. Pharm. Pharm. Sci. 10 (2007) 254-262.
34. A. Passannanti, P. Diana, P. Barraja, F. Mingoia, A. Lauria, G. Cirrincione, Pyrrolo [2,3-d][1,2,3]triazoles as potential antineoplastic agents, Heterocycles 48 (1998) 1229-1235.
35. M. Jilino, F.G. Stevens, Antitumour polycyclic acridines. Part 5. Synthesis of 7H-pyrido[4,3,2-kl]acridines with exploitable functionality in the pyridine ring, J. Chem. Soc. Perkin Trans. 1 (1998) 1677-1684.
36. L. Zhou, A. Amer, M. Korn, R. Burda, J. Balzarini, E. De Clercq, E.R. Kern, P.F. Torrence, Synthesis and antiviral activities of 1,2,3-triazole functionalized thymidines: 1,3-dipolar cycloaddition for efficient regioselective diversity generation, Antivir. Chem. Chemother. 16 (2005) 375-383.
37. C.G. Fortuna, V. Barresi, G. Berellini, G. Musumarra, Design and synthesis of trans 2-(furan-2-yl)vinyl heteroaromatic iodides with antitumour activity, Bioorg. Med. Chem. 16 (2008) 4150-4159.
38. L. Di Nunno, A. Scilimati, Decomposition of arylazides by THF/n-butyllithium-II-isolation of 1-aryl-4,5-dihydro-5-hydroxy-1H-1,2,3-triazoles, Tetrahedron 42 (1986) 3913-3920.
39. P. Vitale, A. Scilimati, Five-membered ring heterocycles by reacting enolates with dipoles, Curr. Org. Chem. 17 (2013) 1986-2000.
40. P. Vitale, A. Scilimati, Functional 3-arylisoxazoles and 3-aryl-2-isoxazolines from reaction of aryl nitrile oxides and enolates: synthesis and reactivity, Synthesis 45 (2013) 2940-2948.
41. J. Das, S.N. Patil, R. Awasthi, C.P. Narasimhulu, S. Trehan, An easy access to aryl azides from aryl amines under neutral conditions, Synthesis 11 (2005) 1801-1806.
42. J.J. Talley, Selective inhibitors of cyclooxygenase-2 (COX -2), Prog. Med. Chem. 36 (1999) 201-234.
43. T. Liu, X. Dong, N. Xue, R. Wu, Q. He, B. Yang, Y. Hu, Synthesis and biological evaluation of 3,4-diaryl-5-aminoisoxazole derivatives, Bioorg. Med. Chem. 17 (2009) 6279-6285.
44. K.D. Grimes, A. Gupte, C.C. Aldrich, Copper(II)-catalyzed conversion of aryl/heteroaryl boronic acids, boronates, and trifluoroborates into the corresponding azides: substrate scope and limitations, Synthesis 9 (2010) 1441-1448.
45. A. Da Settimo, O. Livi, G. Biagi, G. Primofiore, G. Masoni, 1,2,3-Triazole derivatives of aryloxyalanoic acids, Farm. Sci. 37 (1982) 728-739.
46. P. Crivori, G. Cruciani, P.A. Carrupt, B. Testa, Predicting blood-brain barrier permeation from three-dimensional molecular structure, J. Med. Chem. 43 (2000) 2204-2216.
47. G. Cruciani, M. Meniconi, E. Carosati, I. Zamora, R. Mannhold, VOLSURF: a tool for drug ADME-properties prediction, in: Drug Bioavailability. Estimation of Solubility, Permeability and Absorption, Meth. and Princ. in Med. Chem, vol. 18, Wiley-VCH publishers, 2003, pp. 406-419.
48. G. Berellini, G. Cruciani, R. Mannhold, Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide angiotensin ii AT1, AT2 and mixed AT1/AT2 receptor antagonists, J. Med. Chem. 48 (2005) 4389-4399.
49. R. Mannhold, G. Berellini, E. Carosati, P. Benedetti, Use of MIF-based VolSurf descriptors in physicochemical and pharmacokinetic studies, in: G. Cruciani (Ed.), Molecular Interaction Fields in Drug Discovery, vol. 27, Wiley-vch Verlag GmbH & Co. KGaA, Weinheim, 2005, pp. 173-193.
50. S. Wold, M. Sjöström, in: B.R. Kowalski (Ed.), Chemometrics: Theory and Application, ACS Symposium Series, Washington, 1977, pp. 243-282.
51. S. Wold, C. Albano, W.J. Dunn III, U. Edlund, K. Esbensen, P. Geladi, S. Hellberg, E. Johansson, W. Lindberg, M. Sjöström, Multivariate data analysis in chemistry, in: B.R. Kowalski (Ed.), Chemometrics: MaThematics and Statistics in Chemistry, 1984, pp. 17-96.
52. V. Barresi, C. Bonaccorso, G. Consiglio, L. Goracci, N. Musso, G. Musumarra, C. Satriano, C.G. Fortuna, Modeling, design and synthesis of new heteroaryl ethylenes active against MCF-7 breast cancer cell-line, Mol. Biosyst. 9 (2013) 2426-2429.